Hims & Hers Health reported Q1 results missing expectations with revenue up only 4% year-over-year and US revenue down 8%. Earnings per share fell to -$0.40 from $0.20 last year, while monthly revenue per subscriber declined 6% to $80 despite a 9% increase in total subscribers to about 2.6 million. Meanwhile, Trian Fund Management is exploring a possible take-private deal for Wendy's, causing Wendy's shares to rise 4.4% in premarket trading. The potential buyout is still uncertain as financing talks continue without a formal offer. These developments highlight challenges in healthcare subscription growth and active investor interest in fast-food sector consolidation.
Hims & Hers Health has been upgraded to a buy rating due to stronger-than-expected sales of its branded GLP-1 drug Wegovy, which shipped 125,000 units in six weeks. Management now expects over 100,000 monthly new weight-loss subscribers, restoring co...
Hims & Hers Health increased its full-year 2026 revenue guidance to $2.8-$3.0 billion despite reporting a quarterly EPS loss impacted by restructuring charges. The company showed strong subscriber growth nearing 2.6 million and high engagement with 9...
Shares of Hims & Hers Health dropped after JPMorgan lowered its price target from $35 to $33 following a mixed first-quarter report and a strategic shift from compounded to branded GLP-1 medications. Despite the cut, JPMorgan maintained an Overweight...
Hims & Hers shares fell about 14% in pre-market trading following a disappointing Q1 report, attributed to timing of the Novo Nordisk deal and tough year-over-year comparisons. Despite the initial drop, analysts see the Q2 guidance beat and raised fu...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
